FDA Authorizes New Combined At-Home Test for Covid, Flu

New Post Public Reply Private Reply Replies (0) Message Board
someconcerns
623
FDA Authorizes New Combined At-Home Test for Covid, Flu and RSV
The first-ever home test for people with symptoms of COVID-19, the flu, and respiratory syncytial virus (RSV) will be available without a prescription.
By Korin Miller
Published on May 18, 2022

Fact checked on May 18, 2022 by Rich Scherr, a journalist and fact-checker with more than three decades of experience.

The U.S. Food and Drug Administration (FDA) has authorized the first-ever home test for people with symptoms of COVID-19, the flu, and respiratory syncytial virus (RSV), giving users a one-stop approach to help diagnose their condition.

Consumers don't need a prescription to access the first-of-its-kind test, which is called the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test.

"While the FDA has now authorized many COVID-19 tests without a prescription, this is the first test authorized for flu and RSV, along with COVID-19, where an individual can self-identify their need for a test, order it, collect their sample and send it to the lab for testing, without consulting a healthcare professional," Jeff Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health, said in a statement.

Here's a closer look at the new test, how it works, its cost, availability, and more.

The process of purchasing, administering, and obtaining results from the new Labcorp Seasonal Respiratory Virus RT-PCR DTC Test is relatively straightforward, though slightly more time consuming than the at-home COVID-19 tests that were previously made available to the public.

The seasonal respiratory virus collection kits can be purchased online or in a store without a prescription. The kits will be available starting in early June through Labcorp's OnDemand platform.

The kit will cost $169, but there would be no upfront cost for those who have insurance and are experiencing symptoms, Labcorp publicist Jacob Rund told Health. Those who don't have insurance would be required to pay up front when ordering the kit.

Once the kit is received, patients collect a sample using a nasal swab, much like the at-home COVID tests. Samples can be self-collected by those who are 18 and older. Individuals 14 years and older can self collect samples with adult supervision, the FDA said. Anyone younger than 14 must have adult assistance to collect the sample.

The test can identify and differentiate several respiratory viruses at the same time, the FDA said, including influenza A and B, RSV, and SARS-CoV-2, the virus that causes COVID-19. Patients who test positive for any of these conditions are advised to have a follow-up with a healthcare provider.
How to Take An At-Home COVID-19 Test and What to Do If You Test Positive
Timeline for Test Results

Unlike the pre-existing at-home COVID tests, which provide results in about 15 minutes, the new seasonal respiratory virus swab must be sent to Labcorp for testing in order to get results. Results are provided to patients through an online portal.

The FDA doesn't give a timeline for delivery of results, but Labcorp says on its website that the average time for results of the similar physician administered version of the test is one to two days "from the date of the specimen pickup."

In other words, once your sample arrives at the lab, it's likely going to take another day or two to obtain your results—if the lab isn't backed up, William Schaffner, MD, an infectious disease specialist and professor at the Vanderbilt University School of Medicine, told Health.

The time delay in receiving results from the test is an issue that Dr. Schaffner and others say may ultimately impact the popularity of this new offering.

"You need that test result as quickly as possible," said Dr. Schaffner. "I can't see that this will help you very much." Patients, he said, will need to wait for the test to arrive at their home, then must obtain a sample, ship it to a lab, and wait for results. "That will take days," said Dr. Schaffner.

Other medical experts expressed similar concerns about the timeline for results, pointing out that the idea of being able to test yourself for the flu at home is great, but the reality of the test falls short of being a true game-changer.

"It's a good step forward," Amesh Adalja, MD, a senior scholar at the Johns Hopkins Center for Health Security, told Health. "However, this is a test that has to be sent to a laboratory for processing and results."

"What really will be game-changing and is needed are at-home tests that give results at home for influenza, RSV, sexually transmitted infections, and other common infectious disease," said Dr. Adalja. "For high utilization or optimal utilization, a test that [provides] results in the home—like COVID and HIV tests do—is required."

More People Are Using At-Home Tests to Diagnose COVID—How Will We Know if There's Another Surge?

Impact on Treatment and Easing Case Loads For Providers

Having access to at-home tests for the flu, COVID-19, and RSV has the potential to reduce the strain on health care providers and even reduce the risk of spreading infections. Though here, as well, experts predict there may be some challenges.

"To a degree, it would decrease interactions and infected people coming into waiting rooms," Thomas Russo, MD, professor and chief of infectious disease at the University at Buffalo in New York, told Health.

"It could also lighten the queue," Dr. Russo added, noting that it would free up doctors to treat other people.

But the at-home test is not a perfect solution, Dr. Russo said. Given the long lag time between developing symptoms, receiving and taking the at-home test, and getting the results, patients may not be able to get medication in time.

"The sooner you treat with Tamiflu for the flu or Paxlovid for COVID-19, the better your results," Dr. Russo said. "The test is not going to be optimal in terms of timeliness and intervention."

Many doctors will write you a prescription for Tamiflu, for example, before your test result comes back positive, just in case, he pointed out.

That lag time could even raise the risk that patients become sicker with either illness before getting needed care, ultimately arriving at a doctor's office or hospital in worse shape—and using even more healthcare resources than if they had seen their doctor in the first place, Dr. Russo said.

The idea of an at-home test for COVID, the flu, and RSV is promising, Dr. Russo said. But to be truly effective, the test would need to provide users with at-home test results. And its price would need to be cheaper.

"This is just not optimal right now," Dr. Russo said.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ACLS Expands Fellowship Program for Emerging Scholars

Updated Category News Views 82

Expanding Opportunities in Religious Scholarship Here's something you don't see every day: a program that's actually trying to bridge academia and the practical world. The American Council of Learned Societies (ACLS) is rolling out its second wave of their Graduate Internships on the Spiritual Infrastructure of the Future for 2027, backed by the Templeton Religion Trust....

Continue Reading
Island Pacific Opens 22nd Store in Eagle Rock, L.A.

Updated Category News Views 103

Winning the Grocery Game One Store at a Time Here's the scoop—Island Pacific Seafood Market just rolled up the shutters on their 22nd supermarket at 4044 N. Eagle Rock Boulevard in the bustling hub of Glassell Park, Los Angeles. This ain't just some ho-hum store opening; it's a celebration rooted in Filipino heritage, smack in the middle of Northeast L.A., where culture...

Continue Reading
Choosing Lakefront Flooring: A Practical Guide for Owners

Updated Category News Views 87

Understanding Lakefront Challenges Owning a lakefront rental sounds like a dream, right? But the reality involves a mixed bag of conditions that can chew up flooring faster than a pair of puppy claws on exposed oak. We're talking about moisture, sand, and constant guest traffic making these properties a hot mess if you're not careful. Waterproof Vinyl: The Smart Bet...

Continue Reading
ImmunoGenesis Showcases STING Agonist Progress at SITC

Updated Category News Views 113

STING Agonists: The Next Frontier in Glioblastoma Treatment? Out there in the weeds of immunotherapy, ImmunoGenesis is gearing up for its moment at the SITC 2026 Annual Meeting with its STING agonist, IMGS-203. The stakes are skyscraper-high as this novel treatment makes a play against recurrent glioblastoma (GBM)—one tough cookie in the realm of brain cancers....

Continue Reading
Ecovyst Ups Outlook Amid Strong Q3 Results

Updated Category News Views 35

A Bold Leap Forward Ecovyst, mighty in the sulfuric acid trade, just dropped news hotter than a griddle on a sizzling morning. Sales surged by 51% in Q3 to a solid $308.6 million, credited to smart moves and timely acquisitions. Not just puffery here; these folks are redirecting the narrative and it's showing in the numbers. Imagine a company selling parts of itself to...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 64

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
Fixify's AI Solution Boosts MSP Service Capacity

Updated Category News Views 163

Unleashing AI on the MSP Help Desk Chaos Look, managed service providers (MSPs) are always grappling with a circus act—juggling customer growth against swelling staffing costs. Fixify tossed its hat in the ring with a new tool that promises to let the AI do the heavy lifting on those routine IT support tickets. They said, 'Why not let the bots take the grunt work?' Now,...

Continue Reading
Risk Map 2027: Navigating Travel Safety Worldwide

Updated Category News Views 51

Navigating the Complexities of Global Travel Safety Here's the thing folks—a traveler's peace of mind isn't just about sun hats and passports anymore. We're talking pressing global safety dynamics as revealed in the 2027 Risk Map. This ain't your average vacation checklist; it's a deep dive into the evolving tapestry of global security. Whether you’re hopping from the...

Continue Reading
Riley Permian's Q3: Cash Flow Boost & Debt Cut

Updated Category News Views 122

Riley Permian is striding with a swagger through the third quarter of 2026, and you’ve got to tip your hat to them for all the right moves. But don’t get comfy, there's a fair bit to unpack, and not all of it will make you want to reach for the champagne. Oil Production and Cash Flow Surge Setting the pace, Riley cranked up oil production by a hearty 20% from the...

Continue Reading
GomSpace Eyes SEK 1.6 Billion Revenue by 2030

Updated Category News Views 5

Cracking Open GomSpace's Q3 Gains You don't just stumble upon profitability in this market; that's for sure. GomSpace, however, seems to have a knack for finding its stride amidst the chaos. In their latest earnings report, it looks like they're not just coasting—they're powering through with profitable growth in the third quarter. Who would have thought? These folks...

Continue Reading

Top 5 Most Recently Viewed Articles

Aspo Plc Launches Innovative Incentive Plans to Enhance Growth

Updated Category News Views 240

Aspo Plc Implements New Incentive Programs for Employees Aspo Plc has made a significant move to foster growth and enhance employee motivation by introducing updated remuneration strategies. These adjustments are set to take effect in 2025 and are aimed at aligning the performance of key employees with the overall strategic goals of the company. Aligning Interests Through...

Continue Reading
Trifork Teams Up with Replik: Innovating Legal Services

Updated Category News Views 197

Trifork Partners with Replik for Legal Tech Innovation In an exciting development in the legal tech sector, Trifork Group AG has forged a strategic partnership with Replik A/S, acquiring a 10% stake in the company. This alliance is set to enhance Replik's growth trajectory by broadening its product range and integrating advanced technology and artificial intelligence into...

Continue Reading
Leverage Welcomes Jarett Hughes as First CEO and President

Updated Category News Views 281

Leverage Appoints Jarett Hughes as New Leader Leverage has announced the appointment of Jarett Hughes as its inaugural president and chief executive officer. This new advocacy organization aims to enhance the economic well-being and opportunities available to older Coloradans. Backed by a significant investment from the Next50 Foundation, Leverage intends to collaborate...

Continue Reading
RBC Adjusts Randstad Price Target Amid Market Uncertainty

Updated Category News Views 74

RBC Capital Lowers Randstad's Stock Price Target RBC Capital has recently adjusted its outlook on Randstad (RAND:NV), a prominent player in the staffing industry. The investment firm has reduced its price target for Randstad's stock from €49.00 to €46.00. Along with this modification, RBC has retained its Sector Perform rating, indicating a balanced view on the...

Continue Reading
Legal Class Actions: Investors Urged to Act for Their Rights

Updated Category News Views 196

Investors Encouraged to Take Action In light of recent class action lawsuits, investors are encouraged to reach out to legal experts regarding their rights. The Law Offices of Frank R. Cruz are reminding shareholders of significant lawsuits impacting the companies Quanex Building Products Corporation (NYSE: NX), Jasper Therapeutics, Inc. (NASDAQ: JSPR), and KBR, Inc....

Continue Reading